ImmunityBio Inc [IBRX] stock is trading at $6.48, up 17.39%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IBRX shares have gain 150.19% over the last week, with a monthly amount glided 207.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunityBio Inc [NASDAQ: IBRX] stock has seen the most recent analyst activity on May 20, 2025, when Piper Sandler upgraded its rating to a Overweight but kept the price target unchanged to $5 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 06, 2025, and set its price target to $8. On January 10, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $6 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $4 on May 12, 2023. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on August 03, 2022.
ImmunityBio Inc [IBRX] stock has fluctuated between $1.83 and $5.58 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. ImmunityBio Inc [NASDAQ: IBRX] shares were valued at $6.48 at the most recent close of the market. An investor can expect a potential return of 8.02% based on the average IBRX price forecast.
Analyzing the IBRX fundamentals
ImmunityBio Inc [NASDAQ:IBRX] reported sales of 82.56M for the trailing twelve months, which represents a growth of 425.07%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -3.16%, Pretax Profit Margin comes in at -4.22%, and Net Profit Margin reading is -4.22%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, ImmunityBio Inc’s Current Ratio is 5.77. Also, the Quick Ratio is 5.65. Considering the valuation of this stock, the price to sales ratio is 77.31.
Transactions by insiders
Recent insider trading involved CHRISTOBEL SELECKY, Director, that happened on Jan 20 ’26 when 25000.0 shares were purchased. Officer, Simon Barry J. completed a deal on Jan 20 ’26 to buy 0.57 million shares. Meanwhile, Director CHRISTOBEL SELECKY bought 50000.0 shares on Jan 16 ’26.
